NIPBL: A Protein with Potential as A Drug Target Or Biomarker

Target Name: NIPBL

NCBI ID: G25836

NIPBL

NIPBL: A Protein with Potential as A Drug Target Or Biomarker

NIPBL (Nucleotide-Inhibiting Proteasome-Induced Leukemia) is a protein that is expressed in various tissues of the body, including the brain, spleen, and gastrointestinal tract. It is a key regulator of the proteasome, a complex protein that helps to break down and remove proteins that are no longer needed.

Recent studies have suggested that NIPBL may have potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential mechanism by which NIPBL may be involved in cancer is its role in regulating the activity of the proteasome. Cancer cells often have aberrant proteasomes that are able to accumulate and contribute to the development and progression of cancer. NIPBL has been shown to be able to inhibit the activity of the proteasome, which could make it an attractive target for cancer therapies.

Another potential mechanism by which NIPBL may be involved in cancer is its role in cell survival. Cancer cells often have unique mechanisms for survival that allow them to evade the normal cell death processes that are designed to protect the body. NIPBL has been shown to be involved in these processes, and may be a useful biomarker for cancer.

In addition to its potential role in cancer, NIPBL has also been suggested as a potential drug target for other diseases. For example, NIPBL has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that NIPBL may be a useful target for therapies aimed at these conditions.

NIPBL may also be a potential biomarker for autoimmune disorders. autoimmune disorders occur when the immune system becomes abnormally active and attacks the body's own tissues. NIPBL has been shown to be involved in the regulation of immune responses, and may be a useful target for therapies aimed at treating autoimmune disorders.

In conclusion, NIPBL is a protein that has been shown to have various roles in various tissues of the body. Its potential as a drug target or biomarker for cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for further research. Further studies are needed to fully understand the role of NIPBL in these processes and to develop effective therapies.

Protein Name: NIPBL Cohesin Loading Factor

Functions: Plays an important role in the loading of the cohesin complex on to DNA. Forms a heterodimeric complex (also known as cohesin loading complex) with MAU2/SCC4 which mediates the loading of the cohesin complex onto chromatin (PubMed:22628566, PubMed:28914604). Plays a role in cohesin loading at sites of DNA damage. Its recruitment to double-strand breaks (DSBs) sites occurs in a CBX3-, RNF8- and RNF168-dependent manner whereas its recruitment to UV irradiation-induced DNA damage sites occurs in a ATM-, ATR-, RNF8- and RNF168-dependent manner (PubMed:28167679). Along with ZNF609, promotes cortical neuron migration during brain development by regulating the transcription of crucial genes in this process. Preferentially binds promoters containing paused RNA polymerase II. Up-regulates the expression of SEMA3A, NRP1, PLXND1 and GABBR2 genes, among others (By similarity)

The "NIPBL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIPBL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets